As an unparalleled pioneer of in vitro diagnostics (IVD) development, Creative Biolabs offers custom service to develop various high-quality IVD antibodies for miR-133a marker. Our IVD antibodies are available for diagnosis of a variety of cardiovascular diseases, including cardiac hypertrophy, mulberry heart disease, cardiomyopathy, heart failure, etc.

MicroRNAs (miRNAs) are endogenous, small conserved ribonucleotides and about 23 nucleotides long, modulating genes by post-transcription repression. miRNAs emerge in the blood in a significantly stable form and has present as potential diagnostic markers in patients with cardiovascular disease. MicroRNA-133 (miR-133) is one of the most investigated and best-characterized miRNAs so far, and it is indispensable for proper skeletal and cardiac muscle development and function. Besides, miR-133 is closely related to cell specification, differentiation, and is downregulated during cardiac hypertrophy, indicating that it may act a role in the underlying pathogenesis. miR-133 has two types: miR-133a and miR-133b, besides, miR-133a has two alleles: miR-133a-1 and miR-133a-2. miR-133a is formed in the skeletal muscle and heart while miR-133b is produced just in the skeletal muscle. The generation of miR-133a is managed by serum response factor (SRF) and myosin enhancer factor-2 (Mef2) in the myocardium.

IVD Antibodies for miR-133a Marker Figure 1. The schematic diagram of miR-1- and miR-133-mediated gene regulation during muscle proliferation and differentiation. Transcription factors can regulate the tissue-specific expression of miR-1 and miR-133 clusters, such as MEF2, MyoD and SRF. miR-133 improves the proliferation of myoblasts and restrains their differentiation through decreasing protein levels of SRF. (Chen, J. F. 2009)

miR-133a Marker of Cardiovascular

Cardiovascular disease (CVD) is involved in the circulatory system, which contains the heart and blood vessels and conveys nutrients and oxygen to the tissues of the body. CVD are situations that influence the heart and blood vessels, such as heart valve disease, heart failure, coronary artery disease, and many other diseases. miRNAs enable to be measured in circulating blood and play as a novel group of blood-based biomarkers. It was demonstrated that miR-133a served an important role in the regulation of cardiac hypertrophy, epigenetic modification, fibrosis, and β-AR signaling. Studies also indicated that miR-133a was a potential therapeutic target for cardiomyopathy. miR-133a is highly expressed in cardiac and skeletal muscle, and its concentrations are reduced in mulberry heart disease (MHD) patients with left ventricular hypertrophy (LVH). The miR-133a level was negatively connected with LVMI (an indicator of LVH) as reported, thus circulating miR-133a could be a promising marker of cardiac hypertrophy in MHD patients.

IVD Antibodies for miR-133a MarkerFigure 2. Effect of miR-133a-CPCs on Cardiomyocyte Apoptosis. These results indicated that miR-133a-CPCs obviously increased cardiac function in a rat myocardial infarction model by decreasing fibrosis and hypertrophy and improving vascularization and cardiomyocyte proliferation. (Izarra, A. 2014)

IVD Antibodies of miR-133a Marker

IVD antibodies are extensively used as diagnostic tools in several different ways. Antibody-based immunoassays are the most commonly used diagnostic methods and are the fastest developing technologies for the analysis of biomolecules. Creative Biolabs offers customers many IVD antibodies against miR-133a marker to diagnose cardiovascular diseases. With our high-affinity IVD antibodies development service, we are confident in providing a great contribute to the success of your projects.

Creative Biolabs also provides IVD antibodies for various other targets. Please feel free to contact us for more information and a detailed quote.


  1. Chen, J. F. (2009). “microRNAs and muscle disorders.” Journal of cell science 122(1), 13-20.
  2. Izarra, A. (2014). “miR-133a enhances the protective capacity of cardiac progenitors cells after myocardial infarction.” Stem cell reports 3(6), 1029-1042.
  3. Mishra, P. K. (2014). “Is Mir-133a a Promising Therapeutic Target for Heart Failure?.” Journal of Diabetes & Metabolism 5: e118.

For lab research use only.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-357-2254
Fax: 1-631-207-8356
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Follow us on:
Copyright ©2011 - 2020 Creative Biolabs.